A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
Public ClinicalTrials.gov record NCT05171855. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants were adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period in study TCH-306 (foresiGHt; NCT04615273).
Study identification
- NCT ID
- NCT05171855
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 220 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 23 Years to 81 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 16, 2021 (Actual)
- Primary completion
- Dec 23, 2024 (Actual)
- Completion
- Dec 23, 2024 (Actual)
- Last update posted
- Jul 7, 2026
2021 – 2024
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ascendis Pharma Investigational Site | Phoenix | Arizona | 85048 | — |
| Ascendis Pharma Investigational Site | Torrance | California | 90509 | — |
| Ascendis Pharma Investigational Site | Chicago | Illinois | 60611 | — |
| Ascendis Pharma Investigational Site | Indianapolis | Indiana | 46202 | — |
| Ascendis Pharma Investigational Site | Boston | Massachusetts | 02114 | — |
| Ascendis Pharma Investigational Site | Dearborn | Michigan | 48126 | — |
| Ascendis Pharma Investigational Site | Rochester | Minnesota | 55905 | — |
| Ascendis Pharma Investigational Site | St Louis | Missouri | 63110 | — |
| Ascendis Pharma Investigational Site | Las Vegas | Nevada | 89148 | — |
| Ascendis Pharma Investigational Site | Reno | Nevada | 89511 | — |
| Ascendis Pharma Investigational Site | New York | New York | 10017 | — |
| Ascendis Pharma Investigational Site | Portland | Oregon | 97239 | — |
| Ascendis Pharma Investigational Site | Dallas | Texas | 75390 | — |
| Ascendis Pharma Investigational Site | San Antonio | Texas | 78232 | — |
| Ascendis Pharma Investigational Site | Seattle | Washington | 98108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05171855, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05171855 live on ClinicalTrials.gov.